Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2005
03/31/2005WO2004083241A3 Btc-interacting proteins and use thereof
03/31/2005WO2004080148A3 Novel nucleic acids and polypeptides
03/31/2005WO2004075838A3 Method and compositions for the treatment of meconium aspiration syndrome
03/31/2005WO2004074486A3 Fusion proteins of interferon alpha muteins with improved properties
03/31/2005WO2004067719A3 Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
03/31/2005WO2004056965A3 Nucleic acids encoding antifungal drug targets and methods of use
03/31/2005WO2004056314A3 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
03/31/2005WO2004048325A3 Modulation of jagged 1 expression
03/31/2005WO2004043287A3 Novel compositions that enhance production performance in avians
03/31/2005WO2004031276A3 Method of inducing maturation of dendritic cells and uses therefor
03/31/2005WO2004010951A8 Method of treating tumors
03/31/2005WO2004003149A8 Cngh0005 polypeptides, antibodies, compositions, methods and uses
03/31/2005WO2003096877A3 Prevention and treatment of streptococcal and staphylococcal infection
03/31/2005WO2003072754A3 Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
03/31/2005WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2005WO2003027308A3 56294 and 56629, novel human metalloproteases and uses thereof
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005WO2003012052A3 Specific inhibition of gene expression by small double stranded rnas
03/31/2005WO2002083915A8 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
03/31/2005WO2002072753A3 Thymidylate synthase peptides that bind to thymidylate synthase messenger rna
03/31/2005WO2002067968A9 14-3-3 binding molecules as sensitizers for anticancer therapies
03/31/2005US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070699 Nucleotide sequences coding low density lipoprotein receptor-related protein 5 for use as tools in diagnosis and treatment of osteoporosis; high bone mass and bone disorders
03/31/2005US20050070692 Anti-interleukin-1 beta analogs
03/31/2005US20050070691 Polypeptides of moraxella (branhamella) catarrhalis
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070499 Administering neuropeptide y inhibitor
03/31/2005US20050070498 Enteral formulation
03/31/2005US20050070497 Diabetes, insulin resistance and obesity for example
03/31/2005US20050070495 Inhibition of DNA modulation caused by mutated p53
03/31/2005US20050070494 Transforming growth factor-beta response element decoys and methods
03/31/2005US20050070493 Methods and compositions for treating Parkinson's disease
03/31/2005US20050070492 Use of a ribozyme for inhibiting gene expression; screening for oligonucleotide antisense agents
03/31/2005US20050070484 Treating retinopathy both of diabetes and prematurity, or tumor growth
03/31/2005US20050070480 Peptide arginals and methods for treating disseminated intravascular coagulation
03/31/2005US20050070479 Oligo or polyalkylene glycol-coupled thrombin inhibitors
03/31/2005US20050070478 T cell antigen receptor peptides
03/31/2005US20050070477 Lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction; for example protease inhibitors; treating inflammatory lung conditions such as asthma, chronic obstructive pulmonary disease
03/31/2005US20050070476 inducing new bone synthesis using myb induced myeloid protein-1 of SEQ ID NO: 8; homologous with neutrophil chemokine protein; regulates recruitment and/or differentiation of osteoblast and osteoclast precursor cells; osteoporosis
03/31/2005US20050070475 anti-viral peptide-albumin conjugate with maleimide group for bonding cysteine of albumin; for bonding mobile blood components; human immunodeficiency virus; improved half-life
03/31/2005US20050070474 Methods of treatment and compositions therefor
03/31/2005US20050070473 administering parathyroid hormone; antiapoptotic agents; bone disorders
03/31/2005US20050070472 Treatment of pancreatitis with amylin
03/31/2005US20050070471 cultivation of tumour cell line up to confluence,incubation with a serum-free medium for 48 hours, addition of 1 mg/ml of native human AT III, incubation for 48 hours, extraction of the medium supernatant, realization of the bFGF-stimulated endothelial cell, proliferation assay, analysis of the AT III
03/31/2005US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/31/2005US20050070469 oxyntomodulin a polypeptide is administered to a obese mammal by oral, parenteral, mucosal, rectal subcutaneous or transdermal administration
03/31/2005US20050070468 Use of fk506 and analogues for treating allergic diseases
03/31/2005US20050070467 Antitumor agent
03/31/2005US20050070466 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference
03/31/2005US20050070465 Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon
03/31/2005US20050070463 membrane proteins associated with LPSs (lipopolysaccharides), for inducing maturation of dendritic cells; membrane fraction has a proteoglycan titer, represented by the sum of the contents of galactose and of proteins, between 1.2 g/l - 3.4 g/l for galactose and between 7.5 g/l - 14.9 g/l for proteins
03/31/2005US20050070461 Means and methods for altering the motility of the gastrointestinal tract
03/31/2005US20050070460 topically administering to the respiratory tract of a patient with infection, an immune response modifier compound in specific dosage to reduce infection by the agent
03/31/2005US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor
03/31/2005US20050070015 Methods of controlling proliferation of cancer cells and cell death
03/31/2005US20050070001 Uridine diphosphate/xylose:proteoglycan core protein beta -D-xlosyltransferase (XT) for use as tool in prevention and treatment of chronic inflammatory joint diseases
03/31/2005US20050069988 Recombinant expression systems for production of low solubility foreign proteins specifically aminoglobulin
03/31/2005US20050069987 Engineered nerve growth factor for use as tool in prevention and treatment of obesity
03/31/2005US20050069985 Assay methods and amelioration of muscular dystrophy symptoms
03/31/2005US20050069984 Identification of sortase gene
03/31/2005US20050069983 Nucleotide sequences coding membrane protein for use in identifying modulator for prevention and treatment of herpes viral infection, cell proliferative and autoimmune disorders
03/31/2005US20050069981 Human vascular IBP-like growth factor
03/31/2005US20050069980 Transport protein for use as tool in altering in vivo pharmacokinetics of a pharmaceutical, toxic substance or xenobiotics by modulating an ability to transport acidic amino acids; antitumor agents
03/31/2005US20050069976 Protein-coupled receptor
03/31/2005US20050069971 Identifying modulators of transmembrane protein (PROLIXIN) for use in prevention and treatment of hyperlipidemia, athersclerosis, insulin resistance, diabetes and hypertension
03/31/2005US20050069963 Diagnosing ovarian cell proliferative disorders via concentration of tumor marker antigen in blood; immunoassay
03/31/2005US20050069960 Which induce proliferation of tumor-infiltrating lymphocytes without systemic toxicity associated with the administration of wild-type cytokines; drug screening/design
03/31/2005US20050069943 101 human secreted proteins
03/31/2005US20050069942 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter
03/31/2005US20050069919 Novel human secreted proteins and polynucleotides encoding the same
03/31/2005US20050069915 Antibodies that bind human Dickkopf-1 proteins
03/31/2005US20050069914 Novel glycoproteins and methods of use thereof
03/31/2005US20050069883 Melanin-concentrating hormone receptor antagonist binding protein
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069877 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069871 Polypeptide-human zinc finger protein fpm315-17 and the polynucleotide encoding it
03/31/2005US20050069870 Novel hepatitis C viral sequences for use as tool in detection, treatment and prevention of viral infection; immunotherapy; immunodiagnostics
03/31/2005US20050069869 Nucleotide sequences coding severe acute respiratory syndrome (SARS) spike glycoprotein for use as tool in development of immunoglobulins for prevention and treatment of respiratory system disorders; immunotherapy; imunodiagnostics
03/31/2005US20050069865 Synthetic hcv envelope proteins and their use for vaccination
03/31/2005US20050069589 cross-linkable protein in the form of a solution or suspension; cross-linking agent solution includes an aldehyde and an amino acid containing species reactive with the aldehyde
03/31/2005US20050069578 Reconstitution medium for protein and peptide formulations
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069569 Osteocalcin; enzyme inhibitors; promote bone, teeth growth; administering Dna gene
03/31/2005US20050069559 Lawsonia intracellularis vaccine
03/31/2005US20050069557 A protein neuroglobin derived from neuronal tissue; binging, storage oxygen; therapy for central nervous system disorders
03/31/2005US20050069556 Serology display library; analyzing autologous tumor antigen; drug design; antitumor vaccine containing antigen
03/31/2005US20050069548 Uses of agents that bind immune system components
03/31/2005US20050069544 Pharmaceutical composition and a method of treatment
03/31/2005US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
03/31/2005US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis
03/31/2005US20050069536 Contacting male ejaculate, prior to contact with a female egg, with an effective anti-fertility amount of a pharmaceutical composition, which comprises an antibody that binds a surface exposed epitope of SP22, and a pharmaceutically acceptable carrier
03/31/2005US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/31/2005US20050069532 Prevent bacteria from invading cells; deactivation; degradation of poisons
03/31/2005US20050069531 Enzymatic therapy for vision defects; neovascularization; ion exchanging; removal of wastes
03/31/2005US20050069530 A peptide having the amino acid sequence (SEQ ID NO: 10; enzyme inhibitor of both cystolic and secretory phospholipase A2 (cPLA2 and (sPLA2) activity; antiinflammatory, -ischemic,-carcinogenic agents; rheumatic diseases; acute pancreatitis; infection; neurodegenerative disease; neuronal excitotoxicity
03/31/2005US20050069526 Promoting Recovery from Damage to the Central Nervous System
03/31/2005US20050069523 Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
1 ... 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 ... 3163